University of Leicester?s Clinical Trials Unit Signs Contract to Install MACRO v4.1
The University of Leicester’s Clinical Trials Unit (CTU) has recently signed a contract for the installation of MACRO v4.1, the latest release of InferMed’s electronic data capture (EDC) solution. With the unit having been awarded provisional registration as one of the new UKCRC (UK Clinical Research Collaboration)-approved clinical trials units, InferMed is very pleased to welcome the Leicester CTU as a new user of the MACRO application.
One factor in Leicester CTU's decision to purchase the application was the frequent use of the MACRO solution in several UK CTUs and academic research groups,
Of the 48 UKCRC-registered clinical trials units (CTUs) in the UK, nearly one-third have chosen to adopt MACRO to provide an appropriately validated system for running CTIMPs (Clinical Trials of an Investigational Medicinal Product).
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
